Preparation and preliminary evaluation of SARS-CoV-2 DNA vaccine based on PLGA nanoparticles
10.16438/j.0513-4870.2022-1347
- VernacularTitle:基于PLGA纳米粒的SARS-CoV-2 DNA疫苗的制备及初步评价
- Author:
Ya-qi WU
1
;
Meng LI
2
;
Hao-nan XING
2
;
Da-quan CHEN
3
;
Ai-ping ZHENG
2
Author Information
1. Pharmacy School, Yantai University, Yantai 264005, China; Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Academy of Military Sciences, Beijing 100850, China
2. Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Academy of Military Sciences, Beijing 100850, China
3. Pharmacy School, Yantai University, Yantai 264005, China
- Publication Type:Research Article
- Keywords:
corona virus disease 2019;
SARS-CoV-2 DNA vaccine;
poly (lactic-co-glycolic acid) copolymer;
nanoprecipitation method;
non-viral gene carrier
- From:
Acta Pharmaceutica Sinica
2023;58(6):1677-1684
- CountryChina
- Language:Chinese
-
Abstract:
We constructed and optimized the plasmid DNA (pDNA) Opt-S encoding the gene of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein, using poly (lactic-co-glycolic acid) copolymer (PLGA) as a delivery carrier for pDNA. PLGA-pDNA NPs were loaded by nanoprecipitation and its properties in vitro were preliminary evaluated. The results showed that the prepared PLGA-pDNA NPs were regular morphology, clear edges, with an average particle size of (184.2 ± 2.4) nm, polydisperse index (PDI) of 0.093 ± 0.013, zeta potential of (-68.10 ± 0.36) mV, and encapsulation rate of (98.92 ± 0.22)%. The PLGA-pDNA NPs were stable at -20 ℃ for 7 months and could protect pDNA against nuclease degradation. And they also exhibited sustained release of pDNA in vitro. The PLGA-pDNA NPs have low cytotoxicity and high safety. In addition, in vitro transfection experiments showed that the SARS-CoV-2 S gene could enter cells and be expressed. These results indicate that PLGA-pDNA NPs non-viral gene vector have simple preparation process and good performance, which are expected to provide a new idea for the research and development of SARS-CoV-2 vaccine.
